Sjogren’s Syndrome Presenting with Solely Cutaneous Features
Abstract
:1. Introduction
2. Case Presentation
3. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Ruiz, H.; Sánchez, J.L. Tumid Lupus Erythematosus. Am. J. Dermatopathol. 1999, 21, 356–360. [Google Scholar] [CrossRef] [PubMed]
- Shiboski, C.H.; Shiboski, S.C.; Seror, R.; Criswell, L.A.; Labetoulle, M.; Lietman, T.M.; Rasmussen, A.; Scofield, H.; Vitali, C.; Bowman, S.; et al. 2016 American College of Rheumatology/European League against Rheumatism Classification Criteria for Primary Sjögren’s Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol. 2017, 69, 35–45. [Google Scholar] [CrossRef] [PubMed]
- Ramos-Casals, M.; Brito-Zerón, P.; Font, J. The overlap of Sjögren’s syndrome with other systemic autoimmune diseases. Semin. Arthritis. Rheum. 2007, 36, 246–255. [Google Scholar] [CrossRef] [PubMed]
- Roguedas, A.M.; Misery, L.; Sassolas, B.; Le Masson, G.; Pennec, Y.L.; Youinou, P. Cutaneous Manifestations of Primary Sjögren’s Syndrome Are Underestimated. Clin. Exp. Rheumatol. 2004, 22, 632–636. [Google Scholar] [PubMed]
- Stead, J.; Headley, C.; Ioffreda, M.; Kovarik, C.; Werth, V. Coexistence of tumid lupus erythematosus with systemic lupus erythematosus and discoid lupus erythematosus: A report of two cases of tumid lupus. J. Clin. Rheumatol. 2008, 14, 338–341. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Damiani, J.M.; Levine, H.L. Relapsing polychondritis—Report of ten cases. Laryngoscope 1979, 89, 929–946. [Google Scholar] [CrossRef] [PubMed]
- McAdam, L.P.; O’Hanlan, M.A.; Bluestone, R.; Pearson, C.M. Relapsing polychondritis: Prospective study of 23 patients and a review of the literature. Medicine 1976, 5, 193–215. [Google Scholar] [CrossRef]
- Liu, E.; Daze, R.P.; Moon, S. Tumid Lupus Erythematosus: A Rare and Distinctive Variant of Cutaneous Lupus Erythematosus Masquerading as Urticarial Vasculitis. Cureus 2020, 12, e8305. [Google Scholar] [CrossRef] [PubMed]
- Alexiades-Armenakas, M.R.; Baldassano, M.; Bince, B.; Werth, V.; Bystryn, J.C.; Kamino, H.; Soter, N.A.; Franks, A.G., Jr. Tumid lupus erythematosus: Criteria for classification with immunohistochemical analysis. Arthritis Care Res. Off. J. Am. Coll. Rheumatol. 2003, 49, 494–500. [Google Scholar] [CrossRef] [PubMed]
- Shiboski, S.C.; Shiboski, C.H.; Criswell, L.A.; Baer, A.N.; Challacombe, S.; Lanfranchi, H.; Schiødt, M.; Umehara, H.; Vivino, F.; Zhao, Y.; et al. American College of Rheumatology classification criteria for Sjögren’s syndrome: A data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis. Care Res. (Hoboken) 2012, 64, 475–487. [Google Scholar] [CrossRef] [PubMed]
- Robson, A. The Pathology of Cutaneous T-Cell Lymphoma. Cancer Netw. J. Oncol. 2007. Available online: www.cancernetwork.com/view/pathology-cutaneous-t-cell-lymphoma (accessed on 4 February 2021).
Lab Finding | Normal Range | |
---|---|---|
Complete Blood Count | ||
White blood cells (WBC) | 3.8 × 109 cells/L | 4.5–11 × 109 cells/L |
Hemoglobin (Hgb) | 13.7 g/dL | 13.5–17.5 g/dL |
Hematocrit (Hct) | 42% | 41–50 % |
Liver Enzymes | ||
Aspartate transaminase (AST) | 45 u/L | 5–40 u/L |
Alanine transaminase (ALT) | 63 u/L | 19–25 u/L |
Inflammatory Markers | ||
Erythrocyte sedimentation rate (ESR) | 33 mm/hr | 0–30 mm/hr |
C-reactive protein (CRP) | 2.9 mg/L | <10 mg/L |
Autoimmune Serology | ||
Antinuclear antibody (ANA) | 1:2560, speckled | Negative, <1:80 |
Rheumatoid factor (RF) | 70 IU/mL | 0–20 IU/mL |
Anti-Ro antibody (SSA) | Positive | Negative, <20 |
Anti-La antibody (SSB) | Positive | Negative, <20 |
Complement 3 (C3) | Within normal range | 88–201 mg/dL |
Complement 4 (C4) | Within normal range | 15–45 mg/dL |
Ribosomal P antibody | Negative | Negative, <15 U/mL |
Double stranded DNA antibody (dsDNA) | Negative | Negative, <12 U/mL |
Sm antibody | Negative | Negative, <7 U/mL |
Topoisomerase 1 antibody (Scl 70) | Negative | Negative, <32 U/mL |
Thyroid peroxidase antibody (TPO) | Negative | Negative, <16 U/mL |
Antineutrophil cytoplasmic antibody (ANCA) | Negative | Negative, <20 IU/mL |
Angiotensin converting enzyme (ACE) | Negative | Negative, <40 nmol/mL/min |
Antiphospholipid panel | Negative | None detected APLNegative, <12 IgM/IgA |
Urine Analysis | ||
Protein | None | None |
Red blood cells | None | None |
Serum Protein Electrophoresis | ||
Total Protein | 7.5 g/dL | 6.4–8.3 g/dL |
Albumin | 4.19 g/dL | 3.5–5.0 g/dL |
Alpha 1 globulin | 0.27 g/dL | 0.1–0.3 g/dL |
Alpha 2 globulin | 0.71 g/dL | 0.6–1.0 g/dL |
Beta globulin | 0.68 g/dL | 0.7–1.2 g/dL |
Gamma globulin | 1.65 g/dL | 0.7−1.6 g/dL |
Paraprotein | None | None |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Centala, S.; Park, J.H.; Girnita, D. Sjogren’s Syndrome Presenting with Solely Cutaneous Features. Diagnostics 2021, 11, 1260. https://doi.org/10.3390/diagnostics11071260
Centala S, Park JH, Girnita D. Sjogren’s Syndrome Presenting with Solely Cutaneous Features. Diagnostics. 2021; 11(7):1260. https://doi.org/10.3390/diagnostics11071260
Chicago/Turabian StyleCentala, Sneha, Joyce H. Park, and Diana Girnita. 2021. "Sjogren’s Syndrome Presenting with Solely Cutaneous Features" Diagnostics 11, no. 7: 1260. https://doi.org/10.3390/diagnostics11071260
APA StyleCentala, S., Park, J. H., & Girnita, D. (2021). Sjogren’s Syndrome Presenting with Solely Cutaneous Features. Diagnostics, 11(7), 1260. https://doi.org/10.3390/diagnostics11071260